

ASX MEDIA RELEASE

1 February 2023

Changes to Clarity's Board of Directors

Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that Cheryl Maley has joined Clarity's Board of Directors as a Non-Executive Director. Dr Gillies O'Bryan-Tear has resigned from the Board, with an effective date of 15 May, 2023. These changes will maintain the total number of Clarity Directors at seven, with two Executive Directors and five Non-Executive Directors, and result in a majority of independent Directors in line with the ASX's Corporate Governance Principles and Recommendations 2019.

Ms Maley is an experienced senior leader with over 25 years of experience in the pharmaceutical industry. Her most recent role was the General Manager, Novartis Oncology, Australia and New Zealand. She has a strong strategic, commercial background with a proven track record in product launch excellence and timely patient access to innovative medicines. She has worked in the US, Philippines and Australia with local, regional and global responsibilities.

Clarity's Executive Chairman, Dr Alan Taylor, commented, "We are very pleased to welcome Ms Maley to our Board. Her oncology experience will be highly valuable and relevant for Clarity as our Targeted Copper Theranostic products move closer to commercialisation. Ms Maley's experience and focus on innovation and thought leadership will be of particular importance to Clarity as they are at the core of our values. Additionally, her focus and experience with female leadership in pharmaceuticals will assist in the development of our female colleagues who now make up 67% of our workforce. Our priority at the Board level is to continue to strengthen the Board's skills, knowledge and experience. The current changes will also result in 29% female participation, in line with our commitment made to gender balance at the Board level in our ESG report in November 2022."

"We remain absolutely dedicated to being a leader in our field when it comes to all facets of environmental, social and governance issues. The commercialisation of our "perfect pairing" of copper isotopes looks to address the significant supply challenges and waste issues associated with other isotopes in the radiopharmaceutical field. Our commitment to translating great Australian bench-top science into best-in-class products to diagnose and treat cancers covers many social benefits across research, development, innovation and medicine, and our support of local community groups such as Neuroblastoma Australia and Story Factory extends our social impact beyond our main purpose."

Cheryl Maley, commented on her appointment, "Clarity has made significant progress on advancing its Targeted Copper Theranostics platform to date and I am impressed with the speed of the development and team effort that went into getting all six of its core diagnostic and theranostic products into clinical trials in the US. I am excited to join Clarity's Board of Directors and look forward to working together on further growing the impressive list of Clarity's milestones as the Company accelerates its clinical development and rapidly approaches registrational trials in pursuit of its ultimate goal of improving treatment outcomes for children and adults with cancer."

Ms Maley has a Bachelor of Science Degree, a Diploma of Education, a Master of Business Administration and is a Graduate of the Australian Institute of Company Directors. She has a passion for innovation and has completed formal innovation training both in Australia and USA. She is also a graduate of an Executive Female Leadership Program from Novartis (Switzerland). Ms Maley currently serves as a Non-Executive Director for ASX listed biotech company Medlab Clinical.

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults.

www.claritypharmaceuticals.com

For more information, please contact:

Clarity Pharmaceuticals

Dr Alan Taylor
Executive Chairman
ataylor@claritypharm.com

Citadel-MAGNUS

Catherine Strong
0406 759 268
cstrong@citadelmagnus.com

This announcement has been authorised for release by the Executive Chairman.